Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This follows the authorization of Pfizer's coronavirus vaccine last week.

Moderna COVID-19 vaccine authorized for emergency use in US

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Moderna's COVID-19 vaccine, as expected after an independent panel commissioned by the administration recommended its approval earlier this week. This is the second vaccine now authorized for use in the U.S. under EUA, after the Pfizer -BioNTech vaccine was approved […]

FDA authorizes Moderna's COVID-19 vaccine for emergency use

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces FDA authorization of Moderna COVID-19 Vaccine in U.S.

Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.

Moderna's vaccine – the second approved for use in the U.S. – will bolster the number of available doses, which states desperately need to fend off the pandemic.

FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution

The US Food and Drug Administration authorized Moderna's coronavirus shot for emergency use, making the two-dose vaccine the second to be cleared by US regulators.  Moderna's vaccine can be given to all people in the US over age 18, the FDA said Frida in a news release. The authorization comes a day after an independent panel of experts recommended that FDA greenlight the shot.

The US just authorized Moderna's coronavirus vaccine, making millions more doses available to help curb the pandemic

This doubles the European Commission's commitment to 160 million.

Moderna to Provide 80 Million Additional Doses of Coronavirus Vaccine to European Authorities

Scientific success at last for the company but Moderna stock is not responding with jubilation. Investors need patience now more than ever.

Is This the Sell the News Moment for Moderna Stock?

An FDA panel recommends granting approval for emergency use to Moderna's (MRNA) coronavirus vaccine candidate.

Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing

Moderna has multiple means of developing a great deal of value for its shareholders, making Moderna stock very attractive. The post Why Investors Should Buy Moderna Stock appeared first on InvestorPlace.

Why Investors Should Buy Moderna Stock

Moderna slumped as much as 6.2% on Friday as investors sold off on encouraging news regarding the company's coronavirus vaccine. A panel of Food and Drug Administration experts recommended the vaccine be approved for emergency use on Thursday, a key step that will ready the shot for distribution in the United States as soon as next week. Upon FDA approval, Moderna will become the second authorized coronavirus vaccine provider in the US.

Moderna sinks 6% as investors continue to secure profits from massive vaccine rally

FDA Approves Second COVID-19 Vaccine

Investors can expect billions of dollars in vaccine sales to drive the biotech company's share-price growth.

Will Moderna Stock Hit $200 in 2021?

The vaccine would be the first product delivered by Moderna, and sales of it could bring in more than $8 billion in revenue next year.

Moderna's Vaccine Is Close to Getting a Thumbs-Up. Its Stock Is Taking a Hit.

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, mRNA-1273, got FDA panel backing, in line with expectations, and is likely to be accorded emergency use authorization any time now. An Unsurprising Decision: The 20-0 vote, with one abstention, in favor of issuing an EUA for mRNA-1273 in patients 18 years and older, is not surprising, given the high overall vaccine efficacy of 94.5% and protection across all subgroups, SVB Leerink analyst Mani Foroohar said in a note.

Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine

The Food and Drug Administration (FDA) could authorize Moderna's COVID-19 vaccine for emergency use as early as Friday, Health and Human Services (HHS) Secretary Alex Azar told Good Morning America Friday morning. Distribution of the shot could start this weekend, he added.

Moderna's COVID-19 vaccine could get FDA authorization today, with distribution starting at the weekend, health secretary Alex Azar says

Shares of Moderna Inc. were down 0.1% in premarket trading on Friday after the company said the European Commission now plans to purchase an additional 80 million doses of its COVID-19 vaccine candidate. The commission had previously made a deal for 80 million doses.

E.U. to buy an additional 80 million doses of Moderna's coronavirus vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--European Commission exercises option for additional 80 million doses of Moderna's COVID-19 vaccine candidate.

European Commission Exercises Option for Additional 80 Million Doses of Moderna's COVID-19 Vaccine Candidate

The US regulator says it will move quickly to authorise a second COVID-19 vaccine in the country.

US regulator set to approve Moderna vaccine after backing of assessment panel

Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine has received the go-ahead from an advisory panel of the U.S. Food and Drug Administration, paving the way for the company to secure an emergency use authorization (EUA). What Happened: The Vaccines and Related Biological Products Advisory Committee (VRBPAC) gave the nod on Thursday with 20 members in favor and a single abstention.

Moderna COVID-19 Vaccine Secures FDA Panel's Approval

The US Food and Drug Administration announced Thursday that it "will rapidly work toward finalization and issuance of an emergency use authorization" of Moderna's COVID-19 vaccine. The news comes after an FDA expert advisory panel earlier in the day recommended that the vaccine be approved.

FDA says it will 'rapidly work toward' authorizing Moderna's COVID-19 vaccine

The FDA could issue an emergency use authorization on Friday.

FDA Advisers Vote Unanimously Recommending Authorization of Moderna's Coronavirus Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna receives FDA advisory committee vote supporting Emergency Use for Moderna's vaccine against COVID-19 in the United States.

Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna's Vaccine Against COVID-19 in the United States

This follows the backing and subsequent authorization of Pfizer's vaccine last week.

FDA panel backs Moderna's COVID-19 vaccine for use in the US

An independent advisory committee on Thursday voted 20-0-1 that the benefits of Moderna Inc.'s COVID-19 vaccine candidate outweigh the risks, a recommendation that sets the stage for the likely second FDA authorization of a vaccine during the pandemic.

FDA committee supports authorization of Moderna's COVID-19 vaccine

An influential FDA advisory panel on Thursday overwhelmingly voted to recommend the approval of Moderna's coronavirus vaccine for emergency use.

News for Moderna Stock (MRNA)